TARS Tarsus Pharmaceuticals Inc Total Asset Value of Company

High barriers to entry and patent protection for ophthalmological drug delivery methods limit competition for Tarsus Pharmaceuticals (TARS). An assessment of controlled resources demonstrates current capital density, with the latest parameter standing at 553.33. Business profitability is based on exclusive sales of the drug XDEMVY. The stability of the scientific core is complemented by the planned expansion of the sales representative and trial manager workforce.

TARS (Tarsus Pharmaceuticals) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Tarsus Pharma (TARS)

- current quotes and average value forecast:

Market Chart tarsusrx.com|TARS - Price Target Chart

- market capitalization data:

Market Valuation Tarsus Corp|TARS - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Tarsus Pharmaceuticals|TARS - Book Capitalization|Market Capitalization to Book Value Ratio tarsusrx.com|TARS - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Tarsus Pharmaceuticals|TARS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Tarsus Corp|TARS - Company Aggregate Debts|Debts to Book Capitalization Tarsus Corp|TARS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Tarsus Pharmaceuticals|Interim Coverage Ratio tarsusrx.com

- net income and valuation multiples indicators:

TARS - Company Net Income

Fundamental valuation:Tarsus Pharmaceuticals

Manufactured products of Tarsus Pharmaceuticals

Investors are verifying the issuer's stability by analyzing resource efficiency, comparing returns against the volume of controlled assets. This valuation of the company's financial assets is based on a reverse ROA calculation, reflecting the aggregate of capital and liabilities; for Tarsus Pharmaceuticals (TARS), growth in this metric confirms business scaling driven by the commercialization of a unique drug and the strengthening of patent superiority in blepharitis therapy.

Key competitors

SMMT - Company Total Asset Base|Aggregate Company Assets Moderna|Vaxcyte Inc - Total Asset Value of Company|Company Total Assets CRMD|MCRB (Seres Therapeutics, Inc) - Aggregate Asset Value|Company Total Assets SPRO (Spero Therapeutics)|Company Total Assets SCYNEXIS Inc SCYX|ANTX - Aggregate Company Assets|Aggregate Asset Value PYPD (PolyPid Ltd.)|YS Biopharma (LSB) - Aggregate Company Assets|Cumulative Company Assets Iterum Therapeutics|PHGE (BiomX Inc) - Company Total Assets|Company Total Assets BioPharma Bio|Cumulative Company Assets SXTP (60 Degrees Pharmaceuticals)|OGEN (oragenics.com) - Aggregate Asset Value|Company Total Assets ONCO (Onconetix Corp)|Company Total Asset Base OpGen Corporation (OPGN)